+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

HIV Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth

  • ID: 5353045
  • Report
  • June 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Abbott Laboratories
  • Aurobindo Pharma
  • Emcure Pharmaceuticals
  • Gritstone Oncology
  • Micro Labs Limited
  • Pharmstandard
  • MORE
HIV Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global HIV drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the HIV drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The HIV Drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider HIV drugs market, and compares it with other markets.

The report covers the following chapters:
  • Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
  • Report Structure - This section gives the structure of the report and the information covered in the various sections.
  • Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by type, by application, by administration.
  • Market Characteristics - The market characteristics section of the report defines and explains the HIV drugs market. This chapter also defines and describes goods and related services covered in the report.
  • Trends and Strategies - This chapter describes the major trends shaping the global HIV drugs market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
  • Impact of COVID-19 - This section describes the impact of COVID-19 on the HIV drugs market.
  • Global Market Size and Growth - This section contains the global historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional Analysis - This section contains the historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values and growth and market share comparison by region.
  • Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
  • Regional Market Size and Growth - This section contains the region’s market size (2020), historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
  • Competitive Landscape - This section covers details on the competitive landscape of the global HIV drugs market, estimated market shares and company profiles for the leading players.
  • Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities and Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for HIV drug companies in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Scope

Markets Covered:

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s); Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s); Protease Inhibitors; Integrase strand transfer inhibitors (INSTIs); Others
2) By Application: Hospital Pharmacies; Retail Pharmacies; Others
3) By Administration: Oral; Parenteral

Companies Mentioned: Gilead Sciences, Inc.; GlaxoSmithKline plc.; Johnson & Johnson; Merck & Co., Inc.; Boehringer Ingelheim International GmbH

Metrics Covered: Number of Enterprises; Number of Employees

Countries: China; India; Japan; Australia; Indonesia; South Korea; USA; Brazil; UK; Germany; France; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, HIV drugs indicators comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Aurobindo Pharma
  • Emcure Pharmaceuticals
  • Gritstone Oncology
  • Micro Labs Limited
  • Pharmstandard
  • MORE
1. HIV Drugs Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction

7. Segmentation By Geography
7.1 Segmentation By Type
7.2 Segmentation By Application
7.3 Segmentation By Administration

8. HIV Drugs Market Characteristics
8.1 Market Definition
8.2 Market Segmentation By Type
8.2.1 Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
8.2.2 Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
8.2.3 Protease Inhibitors
8.2.4 Integrase strand transfer inhibitors (INSTIs)
8.2.5 Others
8.3 Market Segmentation By Application
8.3.1 Hospital Pharmacies
8.3.2 Retail Pharmacies
8.3.3 Others
8.4 Market Segmentation By Administration
8.4.1 Oral
8.4.2 Parenteral
9 HIV Drugs Market Trends and Strategies
9.1 Multi-Class Combination Products For HIV Treatment
9.2 3D Bioprinting Technology
9.3 Increasing Number Of Pipeline Studies and Drug Development
9.4 Global Research Initiatives and Funding
9.5 New Product Innovations
9.6 Strategic Collaborations and Agreements
10 Impact Of COVID-19 On The HIV Drugs Market
10.1 Consumer Perception
10.2 High Mortality Among HIV/AIDS Patients
10.3 COVID-19 Impact On HIV Treatment
10.4 High Demand for HIV and Anti-viral Drugs During COVID-19 Outbreak
10.5 Conclusion
11 Global HIV Drugs Market Size and Growth
11.1 Market Size
11.2 Historic Market Growth, 2015 - 2020, Value ($ Million)
11.2.1 Drivers Of The Market 2015 - 2020
11.2.2 Restraints On The Market 2015 - 2020
11.3 Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
11.3.1 Drivers Of The Market 2020 - 2025
11.3.2 Restraints On The Market 2020 - 2025
12 Global HIV Drugs Market Segmentation
12.1 Global HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
12.1.1 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.1.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
12.1.3 Integrase Strand Transfer Inhibitors (INSTIs)
12.1.4 Protease Inhibitors (PIs)
12.1.5 Others
12.2 Global HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
12.2.1 Hospital Pharmacies
12.2.2 Retail Pharmacies
12.2.3 Others
12.3 Global HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
12.3.1 Oral
12.3.2 Parenteral
13 HIV Drugs Market, Regional and Country Analysis
13.1 Global HIV Drugs Market, By Region, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.2 Global HIV Drugs Market, By Country, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14 Asia-Pacific HIV Drugs Market
14.1 Asia-Pacific HIV Drugs Market Overview
14.1.1 Region Information
14.1.2 Market Information
14.1.3 COVID-19 Impact
14.1.4 Background Information
14.1.5 Government Initiatives
14.1.6 Regulations
14.1.7 Regulatory Bodies
14.1.8 Major Associations
14.1.9 Taxes levied
14.1.10 Corporate Tax Structure
14.1.11 Investments
14.1.12 Major Companies
14.2 Asia-Pacific HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.3 Asia-Pacific HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.4 Asia-Pacific HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.5 Asia-Pacific HIV Drugs Market: Country Analysis
14.6 China HIV Drugs Market
14.7 China HIV Drugs Market Overview
14.7.1 Country Information
14.7.2 Market Information
14.7.3 COVID-19 Impact
14.7.4 Background Information
14.7.5 Government Initiatives
14.7.6 Regulations
14.7.7 Regulatory Bodies
14.7.8 Major Associations
14.7.9 Taxes levied
14.7.10 Corporate Tax Structure
14.7.11 Investments
14.7.12 Major Companies
14.8 China HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.9 China HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.10 China HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.11 India HIV Drugs Market
14.12 India HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.13 India HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.14 India HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.15 Japan HIV Drugs Market
14.16 Japan HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.17 Japan HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.18 Japan HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.19 Australia HIV Drugs Market
14.20 Australia HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.21 Australia HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.22 Australia HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.23 Indonesia HIV Drugs Market
14.24 Indonesia HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.25 Indonesia HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.26 Indonesia HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.27 South Korea HIV Drugs Market
14.28 South Korea HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.29 South Korea HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
14.30 South Korea HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
15 Western Europe HIV Drugs Market
15.1 Western Europe HIV Drugs Market Overview
15.1.1 Region Information
15.1.2 Market Information
15.1.3 COVID-19 Impact
15.1.4 Background Information
15.1.5 Government Initiatives
15.1.6 Regulations
15.1.7 Regulatory Bodies
15.1.8 Major Associations
15.1.9 Taxes levied
15.1.10 Corporate Tax Structure
15.1.11 Investments
15.1.12 Major Companies
15.2 Western Europe HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
15.3 Western Europe HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
15.4 Western Europe HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
15.5 Western Europe HIV Drugs Market: Country Analysis
15.6 UK HIV Drugs Market
15.7 UK HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
15.8 UK HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
15.9 UK HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
15.10 Germany HIV Drugs Market
15.11 Germany HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
15.12 Germany HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
15.13 Germany HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
15.14 France HIV Drugs Market
15.15 France HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
15.16 France HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
15.17 France HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
16 Eastern Europe HIV Drugs Market
16.1 Eastern Europe HIV Drugs Market Overview
16.1.1 Region Information
16.1.2 Market Information
16.1.3 COVID-19 Impact
16.1.4 Background Information
16.1.5 Government Initiatives
16.1.6 Regulations
16.1.7 Regulatory Bodies
16.1.8 Tax Levied
16.1.9 Major Associations
16.1.10 Corporate Tax Structure
16.1.11 Investments
16.1.12 Major Companies
16.2 Eastern Europe HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
16.3 Eastern Europe HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
16.4 Eastern Europe HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
16.5 Eastern Europe HIV Drugs Market: Country Analysis
16.6 Russia HIV Drugs Market
16.7 Russia HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
16.8 Russia HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
16.9 Russia HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
17 North America HIV Drugs Market
17.1 North America HIV Drugs Market Overview
17.1.1 Region Information
17.1.2 Market Information
17.1.3 COVID-19 Impact
17.1.4 Background Information
17.1.5 Government Initiatives
17.1.6 Regulations
17.1.7 Regulatory Bodies
17.1.8 Major Associations
17.1.9 Taxes levied
17.1.10 Corporate Tax Structure
17.1.11 Investments
17.1.12 Major Companies
17.2 North America HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
17.3 North America HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
17.4 North America HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
17.5 North America HIV Drugs Market: Country Analysis
17.6 USA HIV Drugs Market
17.6.1 USA HIV Drugs Market Overview
17.6.2 Country Information
17.6.3 Market Information
17.6.4 COVID-19 Impact
17.6.5 Background Information
17.6.6 Government Initiatives
17.6.7 Regulations
17.6.8 Regulatory Bodies
17.6.9 Major Associations
17.6.10 Corporate Tax Structure
17.6.11 Investments
17.6.12 Major Companies
17.7 USA HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
17.8 USA HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
17.9 USA HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
18 South America HIV Drugs Market
18.1 South America HIV Drugs Market Overview
18.1.1 Region Information
18.1.2 Market Information
18.1.3 COVID-19 Impact
18.1.4 Background Information
18.1.5 Government Initiatives
18.1.6 Regulations
18.1.7 Regulatory Bodies
18.1.8 Tax Levied
18.1.9 Major Associations
18.1.10 Corporate Tax Structure
18.1.11 Investments
18.1.12 Major Companies
18.2 South America HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
18.3 South America HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
18.4 South America HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
18.5 South America HIV Drugs Market: Country Analysis
18.6 Brazil HIV Drugs Market
18.7 Brazil HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
18.8 Brazil HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
18.9 Brazil HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
19 Middle East HIV Drugs Market
19.1 Middle East HIV Drugs Market Overview
19.1.1 Region Information
19.1.2 Market Information
19.1.3 COVID-19 Impact
19.1.4 Background Information
19.1.5 Government Initiatives
19.1.6 Regulations
19.1.7 Regulatory Bodies
19.1.8 Major Associations
19.1.9 Taxes Levied
19.1.10 Corporate Tax Structure
19.1.11 Investment
19.1.12 Major Companies
19.2 Middle East HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
19.3 Middle East HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
19.4 Middle East HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

2. Africa HIV Drugs Market
20.1 Africa HIV Drugs Market Overview
20.1.1 Region Information
20.1.2 Market Information
20.1.3 COVID-19 Impact
20.1.4 Background Information
20.1.5 Government Initiatives
20.1.6 Regulations
20.1.7 Regulatory Bodies
20.1.8 Major Associations
20.1.9 Taxes Levied
20.1.10 Corporate Tax Structure
20.1.11 Investments
20.1.12 Major Companies
20.2 Africa HIV Drugs Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
20.3 Africa HIV Drugs Market, Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
20.4 Africa HIV Drugs Market, Segmentation By Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

2. Global HIV Drugs Market Competitive Landscape
21.1 Company Profiles
21.2 Gilead Sciences, Inc.
21.2.1 Company Overview
21.2.2 Products and Services
21.2.3 Business Strategy
21.2.4 Financial Overview
21.3 GlaxoSmithKline
21.3.1 Company Overview
21.3.2 Products and Services
21.3.3 Business Strategy
21.3.4 Financial Overview
21.4 Johnson & Johnson
21.4.1 Company Overview
21.4.2 Products and Services
21.4.3 Business Strategy
21.4.4 Financial Overview
21.5 Merck & Co., Inc.
21.5.1 Company Overview
21.5.2 Products and Services
21.5.3 Business Strategy
21.5.4 Financial Overview
21.6 Boehringer Ingelheim International GmbH
21.6.1 Company Overview
21.6.2 Products and Services
21.6.3 Financial Overview

2. Key Mergers and Acquisitions In The HIV Drugs Market
22.1 Gilead Sciences Partnered With Gritstone Oncology
22.2 Beximco Pharmaceuticals Acquired Stakes in Sanofi Bangladesh
22.3 CytoDyn Inc. Collaborates With amfAR
22.4 Merck Partnered With Dewpoint Therapeutics
22.5 ViiV Healthcare Collaborated With Chapel Hill
22.6 HOOKIPA Pharma Inc. Partners With Gilead Sciences
22.7 Lyndra Therapeutics Collaborates With Gilead Sciences
22.8 Mylan Acquired Ascendis Health
22.9 Mylan Collaborate With Atomo Diagnostics
22.10 ViiV Healthcare To Collaborate With Janssen

2. HIV Drugs Market Opportunities and Strategies
23.1 Global HIV Drugs Market In 2025 - Countries Offering Most New Opportunities
23.2 Global HIV Drugs Market In 2025 - Segments Offering Most New Opportunities
23.3 Global HIV Drugs Market In 2025 - Growth Strategies
23.3.1 Market Trend Based Strategies
23.3.2 Competitor Strategies

2. HIV Drugs Market Conclusions and Recommendations
24.1 Conclusions
24.2 Recommendations
24.2.1 Product
24.2.2 Place
24.2.3 Price
24.2.4 Promotion
24.2.5 People

2. Appendix
25.1.1 Market Data Sources
25.1.2 Research Methodology
25.1.3 Currencies
25.1.4 Research Inquiries
25.1.5 About the Publisher
25.1.6 Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Aurobindo Pharma
  • Emcure Pharmaceuticals
  • Gritstone Oncology
  • Micro Labs Limited
  • Pharmstandard
  • MORE
This report describes and evaluates the global HIV drugs market. It covers three five years’ period, including, 2015 to 2020, termed the historic period, 2020 – 2025 forecast period and 2025 -2030 the forecast period.

The global HIV drugs market reached a value of nearly $30,520.0 million in 2020, having increased at a compound annual growth rate (CAGR) of 8.1% since 2015. The market is expected to grow from $30,520.0 million in 2020 to $36,460.0 million in 2025 at a rate of 3.6%. The growth is mainly due to the growing prevalence of HIV and government initiatives which is expected to drive the demand for HIV drugs. The market is expected to grow from $36,460.0million in 2025 to $40,303.1 million in 2030 at a CAGR of 2.0%.

Growth in the historic period resulted from increased government support and initiatives, rise in healthcare expenditure, increase in HIV research and development spending, increased incidence of HIV infection, rise in awareness and economic growth in emerging markets. This growth was restricted by challenges due to regulatory changes, patent expiration of drugs, rise in alternative medications and low healthcare access.

Going forward, government initiatives, cheaper interest rates, development in drug discovery and cheaper interest rates will support the market growth. Side effects of HIV drugs, shortage of supply of HIV drugs, impact of COVID-19 and low rate of voluntary screening are major factors that could hinder the growth of the HIV drugs market in the future.

The HIV drugs market is segmented by type into nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors and others. The non-nucleoside reverse transcriptase inhibitors were the largest segment of the HIV drugs market by type, accounting for 29.4% of the total market in 2020. Going forward, it is also is expected to be the fastest growing segment in the HIV drugs market, at a CAGR of 11.1% during 2020-2025.

The HIV drugs market is also segmented by application into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy was the largest segment of the HIV drugs market by application, accounting for 64.6% of the total market in 2020. Going forward, the others segment is expected to be the fastest growing segment in the HIV drugs market, at a CAGR of 5.4%, during 2020-2025.

The HIV drugs market is also segmented by route of admiration into oral and parenteral. The oral was the largest segment of the HIV drugs market by route of administration, accounting for 94.5% of the total market in 2020. Going forward, it is also expected to the fastest growing segment in the HIV drugs market, at a CAGR of 3.7%.

North America was the largest region in the global HIV drugs market, accounting for 51.1% of the total in 2020. It was followed by the Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the HIV drugs market will be Africa and Asia-Pacific, where growth will be at CAGRs of 6.0% and 4.1% respectively. These will be followed by Middle East and North America, where the markets are expected to register CAGRs of 4.9% and 3.5% respectively.

The HIV drugs market is concentrated, with a small number of large players in the market. The top eight competitors in the market made up to 92.9% of the total market in 2020. Major players in the market include Gilead Sciences Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim GmbH and others.

The top opportunities in the HIV drugs market segmented by type will arise in the non-nucleoside reverse transcriptase inhibitors segment, which will gain $6,152 million of global annual sales by 2025. The top opportunities in the HIV drugs market segmented by route of administration will arise in the oral segment, which will gain $5,692.8 million of global annual sales by 2025. The top opportunities in the HIV drugs market segmented by application will arise in the hospital pharmacies segment, which will gain $3,175.7 million of global annual sales by 2025. The HIV drugs’ market size will gain the most in the USA at $2,466 million. Market-trend-based strategies for the HIV drugs market include investing in 3D bioprinting technology, new product innovations, developing multi-class combination products for HIV treatment and investing in strategic collaborations and agreements. Player-adopted strategies in the HIV drugs market include investing in expanding operations through innovative product launches, investing in collaborations and mergers and getting approvals for new drugs for HIV treatment.

The COVID-19 pandemic substantially impacted the market for HIV drugs owing to the supply chain disruptions in the production and distribution of HIV drugs caused during 2020. In addition to this, the coronavirus outbreak also impacted the HIV testing services in all the countries across the globe.

The usage of HIV and other anti-viral drugs post COVID-19 outbreak increased the demand for these drugs attributing to their usage in the treatment of COVID-19 affected patients.

To take advantage of the opportunities, the publisher recommends the HIV drug companies to focus on the use of automation, focus on combination therapy, focus on research and development of innovative products, focus on collaborations, expand in markets with high incidence of HIV, provide competitively priced offerings, premium pricing for innovative drugs, companies should focus on increasing awareness on HIV infection, companies should leverage e-commerce tools to maximize reach, focus on uneducated population and target young population.
Note: Product cover images may vary from those shown
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla
  • Aurobindo Pharma
  • AbbVie
  • Aspen Pharmacare Limited
  • Pharmacare Ltd.
  • Zion Medical
  • Pfizer
  • Abbott Laboratories
  • Alfa Rio Química Ltda.
  • Globe Quimica S/A
  • Nortec Química S.A.
  • Microbiológica Química e Farmacêutica
  • Indústria e Comércio de Medicamentos Labogen S.A.
  • AstraZeneca
  • Gritstone Oncology
  • Enzolytics Inc.
  • BioClonetics Immunotherapeutics, Inc.
  • Dewpoint Therapeutics
  • ViiV Healthcare
  • Lyndra Therapeutics
  • Mylan N.V.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Teva Canada
  • Pharmstandard
  • Pharmasyntez
  • R-Pharm
  • Alium
  • ChemRar Group
  • CytoDyn Inc.
  • Janssen Pharmaceutical
  • Bavarian Nordic
  • Emcure Pharmaceuticals
  • Micro Labs Limited
  • Shanghai Desano Bio Pharmaceutical
  • Northeast Pharmaceutical Group Co. Ltd
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Strides Arcolab Limited
  • Hetero labs limited
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll